Table 1. Univariate analysis of clinico-pathological parameters influencing tumour-specific survival in the group of grade ^a 1 and 2 breast tumours.

Parameter	Tumour-specific survival
	n	events	P-value b
AGR3 protein expression c
AGR3low	40	9
AGR3high	64	31	0.02
Age at diagnosis
<54,5 years	52	13
≥54,5 years	52	27	0.002
Tumour size d
pT1	44	8
pT2-4	59	31	<0.001
Lymph node status d
pN0	53	14
pN1-3	47	22	0.016
Histological type
invasive ductal	92	35
invasive lobular	5	3	0.165
Oestrogen receptor status
negative (IRS e 0–2)	15	6
positive (IRS e 3–12)	59	21	0.636
Progesterone receptor status
negative (IRS e 0–2)	45	20
positive (IRS e 3–12)	39	12	0.108
HER2 status f
negative (0; 1+; 2+)	75	31
positive (3+)	12	2	0.270

^aAccording to Bloom and Richardson, as modified by Elston and Ellis [32].

^bLog-rank test at the two-sided significance level of 0.05.

^cMedian immunoreactive score (IRS) according to Remmele and Stegner [30] was used as cut-off: AGR3 low (IRS 0–4), AGR3 high (IRS 6–12).

^dAccording to TNM classification by Sobin and Wittekind [58].

^eImmunoreactive score (IRS) according to Remmele and Stegner [30].

^fOverexpression of the ERBB2 gene (Her-2/neu) was diagnosed analogously to the threshold of the DAKO-Score system based on IHC assay. Significant P-values are marked in bold face.